Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole virion antigens (SARS-CoV-2 WVA)

SARS-CoV-2 whole virion antigens represent the complete structural assembly of the Severe Acute Respiratory Syndrome Coronavirus 2, including the Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N) proteins (Source: NIH, PMC7405830). In the context of vaccine development, these antigens are typically used in an inactivated form to stimulate a comprehensive immune response that mimics natural infection without causing disease (Source: WHO, "COVID-19 vaccine tracker and landscape"). By presenting the entire virus to the immune system, these antigens elicit a polyclonal antibody response and T-cell activation against multiple viral components, which may offer broader protection compared to single-protein targets (Source: PubMed, PMID: 33428868). In the context of infection, these antigens are responsible for host cell recognition via the ACE2 receptor and the subsequent inflammatory cascade characteristic of COVID-19 (Source: Nature, "The SARS-CoV-2 spike protein as a drug target"). Therapeutic strategies utilizing these antigens primarily focus on prophylactic immunization to prevent severe disease and transmission (Source: PubMed, PMID: 32365313). Monitoring the efficacy of products targeting these antigens involves assessing neutralizing antibody titers and cellular immunity markers like interferon-gamma. Safety considerations include managing common reactogenicity and monitoring for rare adverse events associated with whole-virus platforms.

Other names

Inactivated SARS-CoV-2SARS-CoV-2 viral particlesWhole-virus SARS-CoV-2SARS-CoV-2 structural proteins

Induction of active immunity through the presentation of multiple inactivated viral structural proteins (S, N, M, and E) to the immune system, stimulating the production of neutralizing antibodies and T-cell responses.